<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069004</url>
  </required_header>
  <id_info>
    <org_study_id>P1045</org_study_id>
    <secondary_id>10108</secondary_id>
    <secondary_id>PACTG P1045</secondary_id>
    <nct_id>NCT00069004</nct_id>
  </id_info>
  <brief_title>A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth</brief_title>
  <official_title>Prevalence of Morphologic and Metabolic Abnormalities in Vertically HIV-Infected and Uninfected Children and Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the prevalence of metabolic and physical abnormalities
      in HIV infected (via mother-to-child transmission) and uninfected children and youth.
      Metabolism, body composition, bone density, and other factors will be assessed in
      relationship to participants' exposure to highly active antiretroviral therapy (HAART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in HIV care associated with HAART, many patients on HAART regimens develop
      physical and metabolic problems, including changes in body fat distribution (lipodystrophy),
      osteopenia and osteoporosis, dyslipidemia, and hyperlactatemia. Early studies suggest that
      protease inhibitors (PIs) were directly responsible for HIV Lipodystrophy Syndrome (HLS) and
      skeletal complications in HAART-treated patients. This study will compare HIV infected,
      HAART-treated children and youth and their uninfected counterparts to make connections
      between HAART, HLS, and skeletal and metabolic problems. The study is the first to address
      the prevalence and risk assessment of these complications in children, and will be useful in
      predicting long-term prognosis in HIV patients who use or have used HAART.

      There will be three groups in the study. Group 1 participants will be uninfected volunteers
      who will receive no protocol-specific treatment or other intervention. Vertically infected
      HIV patients in Groups 2 and 3 will continue their current HAART either on a
      non-PI-containing regimen (Group 2) or a PI-containing regimen (Group 3). Screening
      evaluations will be conducted within 30 days prior to study entry. Study evaluations may be
      completed at study entry or over the course of up to 3 study visits. All participants will
      undergo whole body and regional DEXA scans (to assess bone density), measurements to
      determine sexual maturity, and blood work.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>450</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV-Associated Lipodystrophy Syndrome</condition>
  <condition>HIV Lipodystrophy Syndrome</condition>
  <condition>Lipodystrophy</condition>
  <condition>Dyslipidemia</condition>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        For HIV uninfected participants (Group 1)

          -  HIV-1 negative (perinatally HIV-exposed but uninfected participants are eligible)

        For HIV infected participants (Groups 2 and 3)

          -  Mother-to-child (vertically) transmitted HIV infection

          -  Confirmed diagnosis of HIV-1 infection by two positive assays from two different
             samples

          -  For Group 2, cannot have taken a PI-containing regimen in the 12 months prior to study
             entry or have ever received a PI for 2 or more weeks

          -  For Group 3, must currently be taking the same PI-containing regimen taken
             continuously for at least 12 months prior to study entry

        For all participants

          -  Accessible medical and medications history

          -  Parent, legal guardian, or participant willing to give informed consent and willing to
             comply with study requirements

          -  Females who have begun menstruating must have negative pregnancy test

        Exclusion Criteria

          -  Receipt of certain medications, including growth hormone, megestrol acetate, anabolic
             agents, anticytokine agents, systemic ketoconazole, systemic glucocorticoids (except
             if receiving stable physiologic doses), or drugs to treat osteoporosis

          -  Type II diabetes mellitus and unable to omit medication prior to specimen collection

          -  Pregnancy within the last 12 months, currently pregnant, or breastfeeding

          -  History of eating disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Aldrovandi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peggy Borum, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB, Dept. of Ped., Div. of Infectious Diseases</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Med. Ctr., Miller Children's Hosp.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Mother-Child-Adolescent Program CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Pediatric AIDS CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Colorado Denver NICHD CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Med. Ctr., ACTU</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida CDTC Ft Lauderdale NICHD CRS</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases &amp; Allergy</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF - Tampa NICHD CRS</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens &amp; Childrens HIV Program</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane/LSU Maternal/Child CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp. &amp; Health System - Dept. of Peds., Div. of Infectious Diseases</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HMS - Children's Hosp. Boston, Div. of Infectious Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - Robert Wood Johnson Med. School, Div. of Allergy, Immunology &amp; Infectious Diseases</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901-1969</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers - New Jersey Medical School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Med. &amp; Mental Health Ctr.</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hosp. IMPAACT CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr.</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyu Ny Nichd Crs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hosp. Ctr.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine, Div. of Ped. Infectious Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp. Ctr. NY NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Memorial Hospital Rochester NY NICHD CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD CRS</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Med. Univ., Dept. of Peds.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology &amp; Infectious Diseases</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis. 2002 Jan 15;34(2):248-59. Epub 2001 Dec 7. Review.</citation>
    <PMID>11740715</PMID>
  </reference>
  <reference>
    <citation>Smith KY. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J Infect Dis. 2002 May 15;185 Suppl 2:S123-7. Review.</citation>
    <PMID>12001033</PMID>
  </reference>
  <reference>
    <citation>Currier J, Carpenter C, Daar E, Kotler D, Wanke C. Identifying and managing morphologic complications of HIV and HAART. AIDS Read. 2002 Mar;12(3):114-9, 124-5.</citation>
    <PMID>11966241</PMID>
  </reference>
  <reference>
    <citation>Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999 Jun 19;353(9170):2093-9.</citation>
    <PMID>10382692</PMID>
  </reference>
  <reference>
    <citation>Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, Allen HF. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J. 2003 May;22(5):463-5.</citation>
    <PMID>12797313</PMID>
  </reference>
  <reference>
    <citation>Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000 Mar 10;14(4):F63-7.</citation>
    <PMID>10770534</PMID>
  </reference>
  <results_reference>
    <citation>Jacobson DL, Lindsey JC, Gordon CM, Moye J, Hardin DS, Mulligan K, Aldrovandi GM; Pediatric AIDS Clinical Trials Group P1045 team. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010 Mar 13;24(5):687-96. doi: 10.1097/QAD.0b013e328336095d.</citation>
    <PMID>20168204</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2003</study_first_submitted>
  <study_first_submitted_qc>September 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2003</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-Associated Lipodystrophy Syndrome</keyword>
  <keyword>HIV Lipodystrophy Syndrome</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Lipodystrophy</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

